Proper Documentation Format for Digital Rectal Exam (DRE) of the Prostate
While international guidelines provide extensive recommendations on when to perform DRE during prostate cancer screening and follow-up, they do not specify a standardized documentation format for the examination itself. Based on the available evidence and clinical practice standards, here is the essential documentation framework:
Core Documentation Elements
Patient Position and Technique
- Document patient positioning (typically left lateral decubitus or standing, bent forward)
- Note whether examination was completed or limited by patient tolerance
Prostate Characteristics to Document
Size Assessment:
- Estimate prostate volume in cubic centimeters (cc)
- A practical standardization method suggests 10 cc per fingertip surface area of prostate palpated 1
- Document as small (<20 cc), normal (20-40 cc), enlarged (>40 cc), or provide specific estimate
- Note: DRE volume estimates correlate reasonably with ultrasound measurements when standardized (correlation coefficient showing US PV = 11.93 + 0.85 × DRE PV) 1
Consistency:
- Firm/rubbery (normal)
- Hard/indurated (suspicious)
- Boggy/soft (may indicate prostatitis)
Symmetry:
- Symmetric or asymmetric
- If asymmetric, specify which lobe is enlarged or abnormal
Surface Characteristics:
- Smooth (normal)
- Nodular (specify location: right/left lobe, base/mid/apex)
- Irregular
Tenderness:
- Present or absent
- If present, specify location
Median Sulcus:
- Palpable or obliterated
Mobility:
- Mobile (normal)
- Fixed (suggests extracapsular extension if cancer present)
Suspicious Findings
Document any abnormalities that would warrant further investigation:
- Palpable nodules (location, size, consistency)
- Induration
- Asymmetry with firmness
- Loss of lateral margins
Clinical Context from Guidelines
The evidence reveals important limitations of DRE that should inform documentation priorities:
DRE has poor standalone diagnostic performance for prostate cancer screening, with sensitivity of only 0.17 and specificity of 0.92 for clinically significant prostate cancer 2. In men age 45, DRE detected only 0.05% of cancers compared to 0.21% by PSA, with a true-positive detection rate of just 0.22 relative to PSA screening 3.
When DRE is abnormal, only 64% of positive findings correlate with clinically significant prostate cancer, and 61% of these are located in immediate proximity to the rectum 2. Notably, 86% of PSA-detected cancers have normal DRE, even when tumors are located in potentially accessible zones 3.
Practical Documentation Template
A concise documentation format should include:
"DRE: Prostate [size estimate] cc, [consistency], [symmetry], [surface], median sulcus [present/obliterated]. [Nodules/abnormalities if present with location]. Non-tender. Mobile."
Example 1 (Normal): "DRE: Prostate approximately 30 cc, firm, symmetric, smooth surface, median sulcus palpable. Non-tender. Mobile."
Example 2 (Abnormal): "DRE: Prostate approximately 40 cc, firm with 1 cm area of induration in right lateral lobe at mid-gland level. Asymmetric with right lobe enlargement. Non-tender. Mobile."
Key Clinical Caveats
- DRE should not be used as a stand-alone screening test 3
- Guidelines vary widely on DRE frequency in follow-up, ranging from "not recommended as routine while PSA stable" (NICE) to specific intervals (EAU, NCCN) 4
- PSA and PSA density (PSAD) significantly outperform DRE for clinically significant prostate cancer detection (AUC 0.73 for PSAD vs 0.55 for DRE) 2
- DRE findings should always be interpreted in conjunction with PSA, patient age, family history, and ethnicity 5, 6
- In the modern era with multiparametric MRI availability, MRI has superior accuracy for identifying clinically significant prostate cancer compared to DRE 2, 7
The primary value of documenting DRE findings is for longitudinal comparison and identifying the minority of high-risk cancers with palpable abnormalities, not as a primary screening tool.